Testing RO7965032 for geographic atrophy caused by age-related macular degeneration
Tests RO7965032 against a placebo in people with geographic atrophy from macular degeneration.
Plain-language title generated from the registry record
Registry title: A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Key facts
- Where
- Arlington, Erie, Lynchburg, Walnut Creek, and Winston-Salem, United StatesSee the 5 sites
- Phase
- Phase 2
Where in United States
- Texas Retina Associates - ArlingtonArlington, United StatesTaking people
- Erie Retina ResearchErie, United StatesTaking people
- Piedmont Eye CenterLynchburg, United StatesTaking people
- Bay Area Retina Specialists Medical Group - Vestrum - PPDSWalnut Creek, United StatesTaking people
- Piedmont Retina SpecialistsWinston-Salem, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Genentech, Inc.
- Trial code
- NCT07851259EU 2026-527027-10-00
- Record updated
- 26 October 2026
- Original description
This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)Read full original descriptionShow less
A Phase II, Randomized, Double-Masked, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of RO7965032 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Inclusion: Ocular Inclusion Criteria for the Study Eye; BCVA score of >= 35 letters using the ETDRS VA chart at a starting distance of 4 meters; Lesions may be either extrafoveal or subfoveal; Ocular Inclusion Criteria for Both Eyes; Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging; Well-demarcated GA secondary to AMD.
Exclusion: General Exclusion Criteria - History of hypersensitivity, a severe allergic reaction or anaphylactic reaction to any component of the investigational drug injection; Current or prior history of central serous retinopathy; Current or prior history of choroidal neovascularization (CNV) in either eye; History of diabetic macular edema (DME), retinal vein occlusion, corneal transplant, retinal detachment, Stage 3 or 4 macular hole, optic neuropathy, or retinal dystrophy; History of recurrent infectious or inflammatory ocular disease; Ocular Exclusion Criteria for the Study Eye; Aphakia or absence of the posterior capsule in the study eye; Ocular Exclusion Criteria for the Non-Study Eye; Non-functioning non-study eye defined as either BCVA of hand motion or worse or no physical presence of non-study eye (i.e., monocular); Ocular Exclusion Criteria for Either Eye; Proliferative diabetic retinopathy; Active, infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye; Other protocol-defined inclusion/exclusion criteria may apply.